Deferoxamine-Supplemented Ex Vivo Blood Perfusion Improves Myocardial and Endothelial Function in Donation After Circulatory Death Hearts
The Thoracic and Cardiovascular Surgeon · 01.01.2026 · 74 (S 01 S 01) · S1-S70
DOI: 10.1055/s-0046-1817283 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.01.2026. Verfasst von R. Ferencz und 5 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window)
Background
In heart transplantation, particularly with donation after circulatory death (DCD), ex vivo normothermic blood perfusion (BP) is increasingly used to preserve cardiac allografts. The perfusate likely affects myocardial and endothelial protection, especially considering ischemia/reperfusion injury, which is partially induced by reactive oxygen species (ROS). The iron chelator deferoxamine (DFO) binds molecular iron, making it unavailable for ROS production. This study investigates the effect of DFO supplementation during BP of DCD hearts on myocardial and microvascular endothelial function.
Methods
In a rat DCD model, BP maintained hearts with DFO (DCD-BP-DFO group) or placebo (DCD-BP group). After BP, we simulated orthotopic transplant conditions by reperfusing the hearts with blood from another rat via the left atrium, which generated a preloaded and consequently ejecting left ventricle. Thus, we performed a pressure-volume loop assessment using a conductance catheter and an endothelium-dependent microcirculatory assessment using Laser-Doppler perfusion (LDP) technology and acetylcholine stimulation. In a DCD group and a control group, the hearts were not maintained by BP before evaluation. In the control group, no circulatory death was induced. All groups n = 12 Results: The systolic (stroke work [mmHg µL]: Ctrl 480.5 ± 128.5, DCD 260.1 ± 85.7, DCD-BP-HTK 196.9 ± 60.6, DCD-BP-DFO 457.6 ± 79.2; dP/dtmax [mmHg/s]: 1,416.6 ± 81.9, 1,222.5 ± 129.8, 982.7 ± 143.2, 1,523.8 ± 115.1; p < 0.05) and diastolic (dP/dtmin [mmHg/s]: −1,156.3 ± 89.9, −867.6 ± 100.9, −655.0 ± 131.3, −1,000.8 ± 77.6; dV/dtmax [µL/s]: 221.3 ± 45.9, 146.6 ± 48.1, 95.3 ± 21.5, 226.9 ± 43.3; tau [ms]: 45.3 ± 4.8, 76.4 ± 12.3, 117.9 ± 27.2, 64.7 ± 8.3; p < 0.1) function were impaired in DCD and DCD-BP-HTK vs. Ctrl, but significantly improved in DCD-BP-DFO. The relative LDP was reduced in DCD-BP-HTK (0.773 ± 0.075) compared to Ctrl (1.064 ± 0.036) and DCD (1.021 ± 0.067), but close to Ctrl levels in DCD-BP-DFO (0.941 ± 0.058).
Conclusion
The addition of DFO significantly improves ventricular and microvascular endothelial function of DCD hearts in a rat model, restoring cardiac performance close to healthy controls. These findings suggest that targeted pharmacological supplementation tackling ROS during BP may enhance myocardial protection and improve graft quality. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Ferencz, R., Pohl, S., Knust, H., Simm, A., Szabó, G., & Saemann, L. (2026). Deferoxamine-Supplemented Ex Vivo Blood Perfusion Improves Myocardial and Endothelial Function in Donation After Circulatory Death Hearts. The Thoracic and Cardiovascular Surgeon, 74(S 01 S 01), S1-S70. https://doi.org/10.1055/s-0046-1817283
Vancouver
Ferencz R, Pohl S, Knust H, Simm A, Szabó G, Saemann L. Deferoxamine-Supplemented Ex Vivo Blood Perfusion Improves Myocardial and Endothelial Function in Donation After Circulatory Death Hearts. The Thoracic and Cardiovascular Surgeon. 2026;74(S 01 S 01):S1-S70. doi:10.1055/s-0046-1817283
BibTeX
@article{Ferencz2026,
author = {Ferencz, R. and Pohl, S. and Knust, H. and Simm, A. and Szabó, G. and Saemann, L.},
title = {Deferoxamine-Supplemented Ex Vivo Blood Perfusion Improves Myocardial and Endothelial Function in Donation After Circulatory Death Hearts},
journal = {The Thoracic and Cardiovascular Surgeon},
year = {2026},
volume = {74},
number = {S 01 S 01},
pages = {S1--S70},
doi = {10.1055/s-0046-1817283}
}
EUVIMED